Skip to content
Axcess News – Lifestyle
Author:
Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
March 17, 2026
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
March 12, 2026
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
March 5, 2026
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
March 5, 2026
Eupraxia Pharmaceuticals Announces Proposed Public Offering
March 4, 2026
←
Previous Page
1
2